An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Registrational
- Acronyms LEOPARD
- Sponsors Astellas Pharma Europe Ltd
- 12 May 2017 Results published in the Journal of Urology
- 20 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 01 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.